Bay City Capital

Total investments

136

Average round size

24M

Portfolio companies

81

Rounds per year

5.04

Lead investments

15

Follow on index

0.40

Exits

58

Stages of investment
Private EquityEarly Stage VentureLate Stage Venture
Areas of investment
BiotechnologyHealth CareHealth DiagnosticsGeneticsMedical DeviceMedicalLife SciencePharmaceuticalTherapeuticsBiopharma

Summary

Bay City Capital appeared to be the VC, which was created in 1997. The venture was found in North America in United States. The main department of described VC is located in the San Francisco.

This organization was formed by Fred Craves, John Diekman. The overall number of key employees were 9.

For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States. Among the most popular portfolio startups of the fund, we may highlight Pharmion, Hyperion Therapeutics, Merus. The fund has exact preference in some founders of portfolio startups. If startup sums 5+ of the founder, the chance for it to be financed is low. Besides, a startup requires to be at the age of 4-5 years to receive the investment from the fund. We can highlight the next thriving fund investment areas, such as Medical Device, Life Science.

The top activity for fund was in 2013. Despite it in 2019 the fund had an activity. Comparing to the other companies, this Bay City Capital performs on 6 percentage points more the average number of lead investments. When the investment is from Bay City Capital the average startup value is 100-500 millions dollars. The fund is constantly included in 2-6 deals per year. The usual things for fund are deals in the range of 10 - 50 millions dollars. Speaking about the real fund results, this VC is 1 percentage points more often commits exit comparing to other organizations. The top amount of exits for fund were in 2014.

The usual cause for the fund is to invest in rounds with 5-6 partakers. Despite the Bay City Capital, startups are often financed by New Leaf Venture Partners, Sofinnova Investments, Canaan Partners. The meaningful sponsors for the fund in investment in the same round are Novo Holdings, Canaan Partners, Alta Partners. In the next rounds fund is usually obtained by New Enterprise Associates, Sofinnova Investments, Alta Partners.

Show more

Investments analytics

Analytics

Total investments
136
Lead investments
15
Exits
58
Rounds per year
5.04
Follow on index
0.40
Investments by industry
  • Biotechnology (109)
  • Health Care (87)
  • Pharmaceutical (60)
  • Medical (31)
  • Therapeutics (30)
  • Show 34 more
Investments by region
  • United States (124)
  • Netherlands (3)
  • Iceland (2)
  • Ireland (1)
  • Denmark (1)
  • Show 3 more
Peak activity year
2002
Number of Unicorns
3
Number of Decacorns
3
Number of Minotaurs
3

Discover reliable insights

Leverage validated data, identify key contacts and secure funding opportunities for your business.

Quantitative data

Avg. startup age at the time of investment
18
Avg. valuation at time of investment
213M
Group Appearance index
0.76
Avg. company exit year
10
Avg. multiplicator
2.21
Strategy success index
0.90

Need more data?

Get access to full data about investors, including their team, contact information, and historic data.

Latest deals

Company name Deal date Industry Deal stage Deal size Location
Imara 01 Jan 2016 Biotechnology, Health Care, Collaboration, Genetics, Therapeutics, Biopharma Seed 800K United States, Massachusetts, Cambridge
Syntonix Pharmaceuticals 01 Feb 2002 Biotechnology, Health Care Early Stage Venture 35M United States, Massachusetts, Waltham

Similar funds

By same location

By same geo focus

By doing lead investments

How we get our data

At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).

Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.